Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Receivables (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Receivables for 3 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 18.84% to $19.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.4 million through Dec 2025, up 18.84% year-over-year, with the annual reading at $19.4 million for FY2025, 18.84% up from the prior year.
  • Receivables for Q4 2025 was $19.4 million at Nuvation Bio, up from $13.8 million in the prior quarter.
  • The five-year high for Receivables was $19.4 million in Q4 2025, with the low at $3.7 million in Q4 2023.
  • Average Receivables over 3 years is $9.2 million, with a median of $6.1 million recorded in 2025.
  • The sharpest move saw Receivables skyrocketed 340.09% in 2024, then increased 18.84% in 2025.
  • Over 3 years, Receivables stood at $3.7 million in 2023, then surged by 340.09% to $16.3 million in 2024, then rose by 18.84% to $19.4 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $19.4 million, $13.8 million, and $6.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.